Biosynthetic Heparin Production via Chemoenzymatic Sulfation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The reliance on animal sources for heparin production leads to quality control issues, supply shortages, and challenges in detecting contamination, particularly due to environmental factors and infectious diseases affecting porcine populations, and existing biosynthetic heparin methods have not met USP standards for bioequivalence to porcine USP Heparin.
Innovation Solution
A method for producing biosynthetic heparin through chemoenzymatic processes from heparosan, involving specific intermediates with defined disaccharide compositions and enzymatic treatments with 3-O-sulfotransferase isoform 1, 2-O-sulfotransferase, and 6-O-sulfotransferases to achieve bioequivalence with porcine USP Heparin, including the use of sulfate donors like PAPS and enzyme recycling systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal sources (porcine intestine) are used for heparin production, then heparin can be obtained, but quality control issues and contamination risks arise due to environmental factors and infectious diseases
Solution Approach 1:
The patent creates a biosynthetic copy of natural heparin by engineering bacteria to produce heparin with identical disaccharide composition and structure to porcine USP heparin. This copying approach replicates the desired product while eliminating dependence on animal sources, thereby resolving the contradiction between obtaining heparin and avoiding contamination risks
Solution Approach 2:
The patent introduces bacterial cells as an intermediary system that converts heparosan into heparin through controlled enzymatic processes. This intermediary biosynthetic pathway replaces the direct animal source with a controllable microbial system, enabling quality control while eliminating contamination risks associated with porcine populations
2Productivity
If animal sources are used for heparin production, then heparin supply can be maintained, but supply shortages occur when porcine populations are affected by infectious diseases
Solution Approach 1:
By creating a biosynthetic copy of heparin through engineered bacteria, the patent establishes an alternative production source that is independent of porcine populations. This ensures continuous supply stability even when animal sources are compromised by infectious diseases
Solution Approach 2:
The patent changes the production parameter from animal-derived extraction to microbial biosynthesis. This fundamental parameter change in the production system enables reliable heparin supply by transitioning from an uncontrollable animal source to a controllable industrial bioprocess
3Ease of manufacture
If existing biosynthetic methods are used, then heparin can be produced, but the product does not meet USP standards for bioequivalence to porcine USP Heparin
Solution Approach 1:
The patent applies local quality control by specifically targeting and controlling the disaccharide composition at each position in the heparin chain. By ensuring that each disaccharide unit (NS, NS2S, NS6S, NS2S6S) matches the precise composition found in porcine USP heparin, the patent achieves manufacturing precision that meets USP bioequivalence standards while maintaining biosynthetic production
Solution Approach 2:
The patent implements feedback control in the biosynthetic process by monitoring and adjusting enzymatic reactions to achieve the target disaccharide composition. Through controlled sulfation reactions and analytical verification, the process self-corrects to ensure the final product meets USP specifications for bioequivalence
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces biosynthetic heparin that meets USP requirements for anticoagulant activity, molecular weight distribution, and disaccharide composition, ensuring bioequivalence to porcine USP Heparin, addressing supply and quality concerns while avoiding animal-derived contamination risks.
Implementation Method 1
treating the glycosaminoglycan with an enzyme, which is 3-O-sulfotransferase isoform 1 (3OST-1), in the presence of a sulfate donor to produce a biosynthetic heparin batch
Implementation Method 2
A method for producing biosynthetic heparin through chemoenzymatic processes from heparosan, involving specific intermediates with defined disaccharide compositions and enzymatic treatments with 3-O-sulfotransferase isoform 1, 2-O-sulfotransferase, and 6-O-sulfotransferases
Data Source
AI summary
The present disclosure relates to synthesis of heparin, which may be bioequivalent to porcine USP Heparin Sodium. The synthesis may involve three intermediates starting from heparosan.